JAN (NYSE:JAN – Get Free Report) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.
A number of other equities research analysts also recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of JAN from $33.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 1st. UBS Group set a $29.00 target price on shares of JAN in a research report on Thursday, June 18th. Zacks Research downgraded JAN from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Compass Point initiated coverage on JAN in a report on Wednesday. They issued a “neutral” rating and a $37.00 target price for the company. Finally, Wall Street Zen raised JAN from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.31.
Read Our Latest Analysis on JAN
JAN Trading Down 3.4%
JAN (NYSE:JAN – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.18). The firm had revenue of $216.46 million for the quarter, compared to analysts’ expectations of $203.32 million. JAN’s revenue for the quarter was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, analysts expect that JAN will post 0.97 EPS for the current fiscal year.
Institutional Investors Weigh In On JAN
Several large investors have recently modified their holdings of the stock. Engineers Gate Manager LP purchased a new position in JAN in the second quarter valued at approximately $15,274,000. Wellington Management Group LLP bought a new position in JAN during the second quarter valued at $8,739,000. WINTON GROUP Ltd purchased a new stake in JAN in the second quarter worth $2,985,000. Readystate Asset Management LP bought a new stake in shares of JAN in the second quarter valued at $1,724,000. Finally, Greenland Capital Management LP bought a new stake in shares of JAN in the second quarter valued at $575,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.
Key Headlines Impacting JAN
Here are the key news stories impacting JAN this week:
- Positive Sentiment: Monthly dividend provides income support: JAN declared a monthly dividend of $0.0475 per share, equivalent to an annualized yield of approximately 1.8%. The upcoming payments are scheduled for October 28, November 23, and December 29, 2026. JAN dividend announcement
- Positive Sentiment: Revenue growth remains strong: JAN reported quarterly revenue of $216.46 million, up 45.4% year over year and above the $203.32 million analyst consensus. Full-year fiscal 2026 guidance calls for earnings per share of $0.95 to $0.98.
- Neutral Sentiment: Analyst target indicates limited near-term upside: Analysts assign JAN an average price target of $31.71, modestly above the recent trading level. This suggests some potential upside, but not a major revaluation catalyst. JAN receives average analyst price target
- Negative Sentiment: Latest earnings missed expectations: JAN reported earnings of $0.05 per share, falling short of the $0.23 consensus estimate by $0.18. The earnings miss is likely the most important pressure on the stock, despite the better-than-expected revenue and continued growth.
- Negative Sentiment: Upside is being weighed against execution risk: With shares trading near the 50-day moving average and the analyst target only modestly higher, investors may remain cautious until JAN demonstrates that it can convert its revenue growth into stronger profitability.
About JAN
JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.
JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.
The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.
Featured Stories
- Five stocks we like better than JAN
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
Receive News & Ratings for JAN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JAN and related companies with MarketBeat.com's FREE daily email newsletter.
